Literature DB >> 20821177

Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment.

Kinga Musiał1, Danuta Zwolińska.   

Abstract

The system of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may play a key role in atherogenesis of chronic kidney disease (CKD) patients by its impact on matrix accumulation. Connections with inflammation, stress, or endothelial dysfunction are also probable. However, the data on correlations between these parameters in CKD patients are scarce in adults and absent in children. The aim of our study was to evaluate serum concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2, as well as their correlations with markers of stress response (Hsp90-α, anti-Hsp60), endothelial dysfunction (sE-selectin), and inflammation (high-sensitivity C-reactive protein) in CKD children treated conservatively. Thirty-seven patients were divided into two groups according to the CKD stage (gr.CKDI, 19 children with CKD stages 2-3; gr.CKDII, 18 subjects with CKD stages 4-5). Twenty-four age-matched healthy subjects served as controls. Serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, Hsp90-α, anti-Hsp60, and sE-selectin were assessed by ELISA. Median values of MMP-2, MMP-9, TIMP-1, and TIMP-2 were significantly higher in all CKD children vs. controls and were increased in patients with CKD stages 4-5 vs. CKD stages 2-3. Hsp90-α, anti-Hsp60, sE-selectin, and glomerular filtration rate predicted the values of MMPs and TIMPs. Chronic kidney disease in children is characterized by MMP/TIMP system dysfunction, aggravated by the progression of renal failure. Correlations between examined parameters, heat shock proteins, and markers of endothelial damage suggest the possibility of MMP/TIMP application as indicators of stress response and atherogenesis in children with CKD on conservative treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20821177      PMCID: PMC3024084          DOI: 10.1007/s12192-010-0214-x

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  34 in total

1.  Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis.

Authors:  Jason L Johnson; Andrew H Baker; Kazuhiro Oka; Lawrence Chan; Andrew C Newby; Christopher L Jackson; Sarah J George
Journal:  Circulation       Date:  2006-05-15       Impact factor: 29.690

2.  Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells.

Authors:  François Valentin; Jean-Luc Bueb; Pascal Kieffer; Eric Tschirhart; Jeffrey Atkinson
Journal:  Fundam Clin Pharmacol       Date:  2005-12       Impact factor: 2.748

3.  Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.

Authors:  Jacek Rysz; Maciej Banach; Robert A Stolarek; Jaroslaw Pasnik; Aleksandra Cialkowska-Rysz; Robert Koktysz; Mariusz Piechota; Zbigniew Baj
Journal:  J Nephrol       Date:  2007 Jul-Aug       Impact factor: 3.902

4.  The heat shock protein profile in children with chronic kidney disease.

Authors:  Kinga Musial; Krystyna Szprynger; Maria Szczepańska; Danuta Zwolińska
Journal:  Perit Dial Int       Date:  2010-01-15       Impact factor: 1.756

5.  Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.

Authors:  Nadège Lods; Paolo Ferrari; Felix J Frey; Andreas Kappeler; Celine Berthier; Bruno Vogt; Hans-Peter Marti
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

6.  Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.

Authors:  Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Journal:  Atherosclerosis       Date:  2006-02-28       Impact factor: 5.162

7.  Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms.

Authors:  Y Zhang; K McCluskey; K Fujii; L M Wahl
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

8.  Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?

Authors:  M Peiskerová; M Kalousová; M Kratochvílová; S Dusilová-Sulková; J Uhrová; S Bandúr; I M Malbohan; T Zima; V Tesar
Journal:  Kidney Blood Press Res       Date:  2009-10-01       Impact factor: 2.687

9.  Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function.

Authors:  Francesco Addabbo; Francesca Mallamaci; Daniela Leonardis; Rocco Tripepi; Giovanni Tripepi; Michael S Goligorsky; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2007-07-17       Impact factor: 5.992

Review 10.  Autoimmune and inflammatory mechanisms in atherosclerosis.

Authors:  Georg Wick; Michael Knoflach; Qingbo Xu
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  23 in total

1.  Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.

Authors:  Li-Che Lu; Chung-Wei Yang; Wen-Yeh Hsieh; Wan-Hsuan Chuang; Yi-Chang Lin; Chih-Sheng Lin
Journal:  Clin Exp Nephrol       Date:  2015-12-28       Impact factor: 2.801

2.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 3.  Emerging biomarkers of chronic kidney disease in children.

Authors:  Jason H Greenberg; Aadil Kakajiwala; Chirag R Parikh; Susan Furth
Journal:  Pediatr Nephrol       Date:  2017-06-17       Impact factor: 3.714

4.  Heat shock protein 90 inhibition by 17-Dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke.

Authors:  Jia Qi; Yan Liu; Ping Yang; Ting Chen; Xin Zhu Liu; You Yin; Jian Zhang; Feng Wang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 5.  Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases.

Authors:  Hong Zhao; Yanting Dong; Xinrui Tian; Thian Kui Tan; Zhuola Liu; Ye Zhao; Yun Zhang; David Ch Harris; Guoping Zheng
Journal:  World J Nephrol       Date:  2013-08-06

Review 6.  The autoimmune concept of atherosclerosis.

Authors:  Cecilia Grundtman; Georg Wick
Journal:  Curr Opin Lipidol       Date:  2011-10       Impact factor: 4.776

7.  Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Authors:  Chrysanthos Symeonidis; Eleni Papakonstantinou; Asimina Galli; Ioannis Tsinopoulos; Asimina Mataftsi; Spyridon Batzios; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-20       Impact factor: 3.117

8.  Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells.

Authors:  Kalliopi Zafeiropoulou; Theodora Bita; Apostolos Polykratis; Stella Karabina; John Vlachojannis; Panagiotis Katsoris
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

9.  Protective effect of exogenous matrix metalloproteinase-9 on chronic renal failure.

Authors:  Lei Wang; Jue Wang; Yong Wang; Qiang Fu; Yong-Hua Lei; Zhi-Yong Nie; Jianxin Qiu; Ting-Yi Bao
Journal:  Exp Ther Med       Date:  2013-11-15       Impact factor: 2.447

Review 10.  Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery.

Authors:  Ting Gui; Aiko Shimokado; Yujing Sun; Takashi Akasaka; Yasuteru Muragaki
Journal:  Mediators Inflamm       Date:  2012-04-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.